Roche has filed a lawsuit against Stanford University and its spinout Foresight Diagnostics, saying the young cancer test developer was built upon trade secrets it acquired for detecting tumor DNA in the bloodstream.
The suit stems from a nearly decade-old deal that Roche inked with some of Foresight’s founders—Stanford professors Maximilian Diehn and Ash Alizadeh, who specialize in oncology, hematology and liquid biopsy. Diehn and Alizadeh previously helped establish Capp Medical, which Roche bought up in 2015 to gain access to its genomic cancer detection platform, dubbed CAPP-Seq.
According to Roche’s molecular diagnostics divisions, Capp’s technology was used to help develop the drugmaker’s Avenio DNA analysis kits, including assays for non-Hodgkin’s lymphoma and recurrence monitoring. Though the financial details were not disclosed at the time, Roche said in its complaint that it paid out tens of millions of dollars for the company.
And through the deal, Diehn and…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
ORTHOPEDIC REHABILITATION ASSOCIATES OPENS SIXTH COLORADO SPRINGS-AREA OUTPATIENT CLINIC
At 7218 N. Academy Blvd. COLORADO SPRINGS, Colo., Jan. 13, 2023 /PRNewswire/ — Orthopedic Rehabilitation Associates has opened its sixth area outpatient clinic at 7218 N. Academy Blvd. The new clinic operates 10:30 a.m. to […]
Beta Blockers: Why People Are Turning to an Old Drug for High-Stress Moments
Social media rumblings and high-profile celebrity comments suggest more people than ever are popping beta blockers, a medication traditionally used in cardiac care, when they face something anxiety-provoking. Click here to view original post Click […]
Boulder’s Biodesix snags $20M contract, plans move to larger space in Louisville
The biotech company will take over the former Kohl’s location at 919 West Dillon. Click here to view original post
